You are here: Industry Insights > Nusinersen

News List

The Curtain Has Risen on the Competition for the First Generic Drug, so What Other Innovative Drugs in the Rare Disease Field Can We Look Forward to? Xiaobin
January 23, 2025
The CDE website shows Qilu Pharmaceutical applied for the marketing of nusinersen generic. Once controversial for high price, it treats SMA. Now many firms are involved, and SMA treatment progresses.
Reverse Mergers Among Chinese Pharma Firms are Rising Xiaobin
January 23, 2025
Qilu Pharmaceutical applied for marketing of nusinersen injection, becoming the second in China. Nusinersen has a complex history due to high price. SMA treatment has multiple drugs and Chinese firms are making progress, with unmet needs remaining.
History of the “Sky-high Priced” Imported Drug to China: Nusinersen Injection PharmaSources/zhulikou431
November 14, 2019
Nusinersen Injection, the world’s first SMA (Spinal Muscular Atrophy) precision targeted therapy, was completed the intrathecal injection to the first SMA patients in China on Oct. 10, 2019, marking a new milestone of SMA treatment.
Nusinersen Promising for Later-Onset Spinal Muscular Atrophy drugs
April 25, 2019
Nusinersen Promising for Later-Onset Spinal Muscular Atrophy.
Nusinersen enables infants with SMA to regain motor function europeanpharmaceuticalreview
November 03, 2017
Infants with SMA are more likely to show gains in motor function and survive without assisted support when treated with nusinersen…